JP4703650B2 - バニロイドアンタゴニストとして有用なキナゾリノン誘導体 - Google Patents
バニロイドアンタゴニストとして有用なキナゾリノン誘導体 Download PDFInfo
- Publication number
- JP4703650B2 JP4703650B2 JP2007526311A JP2007526311A JP4703650B2 JP 4703650 B2 JP4703650 B2 JP 4703650B2 JP 2007526311 A JP2007526311 A JP 2007526311A JP 2007526311 A JP2007526311 A JP 2007526311A JP 4703650 B2 JP4703650 B2 JP 4703650B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- hydroxy
- compound
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000005557 antagonist Substances 0.000 title description 8
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title description 4
- 150000003839 salts Chemical group 0.000 claims abstract description 41
- -1 quinazolinone compound Chemical class 0.000 claims abstract description 32
- 150000001875 compounds Chemical class 0.000 claims description 62
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 239000002253 acid Substances 0.000 abstract description 19
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 32
- 238000011282 treatment Methods 0.000 description 27
- 208000002193 Pain Diseases 0.000 description 22
- 238000000034 method Methods 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 12
- 208000006673 asthma Diseases 0.000 description 11
- 125000001309 chloro group Chemical group Cl* 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 7
- 108010062740 TRPV Cation Channels Proteins 0.000 description 7
- 102000011040 TRPV Cation Channels Human genes 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 208000023504 respiratory system disease Diseases 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 229960002504 capsaicin Drugs 0.000 description 6
- 235000017663 capsaicin Nutrition 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012981 Hank's balanced salt solution Substances 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 3H-quinazolinyl-4-one Natural products C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 208000033116 Asbestos intoxication Diseases 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 206010003441 asbestosis Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 201000003146 cystitis Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010006002 Bone pain Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 108010025083 TRPV1 receptor Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 229940122629 Vanilloid antagonist Drugs 0.000 description 3
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 206010035653 pneumoconiosis Diseases 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 239000000085 vanilloid receptor antagonist Substances 0.000 description 3
- BPQZYOJIXDMZSX-UHFFFAOYSA-N 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethylpropan-1-amine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21.C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 BPQZYOJIXDMZSX-UHFFFAOYSA-N 0.000 description 2
- VFTOHJFKIJLYKN-UHFFFAOYSA-N 7-nitro-9h-fluoren-2-ol Chemical group [O-][N+](=O)C1=CC=C2C3=CC=C(O)C=C3CC2=C1 VFTOHJFKIJLYKN-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 201000010001 Silicosis Diseases 0.000 description 2
- 241000272534 Struthio camelus Species 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000000604 anti-edema agent Substances 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229960000794 baclofen Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000004317 sodium nitrate Substances 0.000 description 2
- 235000010344 sodium nitrate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940035276 tofranil-pm Drugs 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- 238000010518 undesired secondary reaction Methods 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- NBXJDRUJYQEHDH-UHFFFAOYSA-N 2-amino-4-nitrobenzoic acid;2-methylpropanamide Chemical compound CC(C)C(N)=O.NC1=CC([N+]([O-])=O)=CC=C1C(O)=O NBXJDRUJYQEHDH-UHFFFAOYSA-N 0.000 description 1
- OJVMSICJWQFIOS-UHFFFAOYSA-N 3-(4-chlorophenyl)-7-hydroxy-2-propan-2-ylquinazolin-4-one Chemical compound CC(C)C1=NC2=CC(O)=CC=C2C(=O)N1C1=CC=C(Cl)C=C1 OJVMSICJWQFIOS-UHFFFAOYSA-N 0.000 description 1
- ZXVGFOYXFWKWAV-UHFFFAOYSA-N 3-(4-chlorophenyl)-7-nitro-2-propan-2-ylquinazolin-4-one Chemical compound CC(C)C1=NC2=CC([N+]([O-])=O)=CC=C2C(=O)N1C1=CC=C(Cl)C=C1 ZXVGFOYXFWKWAV-UHFFFAOYSA-N 0.000 description 1
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- XBLNKLVBZMWWLK-UHFFFAOYSA-N 7-amino-3-(4-chlorophenyl)-2-propan-2-ylquinazolin-4-one Chemical compound CC(C)C1=NC2=CC(N)=CC=C2C(=O)N1C1=CC=C(Cl)C=C1 XBLNKLVBZMWWLK-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003557 Asthma exercise induced Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 229940122155 Bradykinin receptor antagonist Drugs 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 229940127597 CGRP antagonist Drugs 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010031009 Oral pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100208026 Rattus norvegicus Trpv1 gene Proteins 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 238000000297 Sandmeyer reaction Methods 0.000 description 1
- 206010049002 Scar pain Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010040744 Sinus headache Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 206010046823 Uterine spasm Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229940011681 elavil Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000010659 intrinsic asthma Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004086 maxillary sinus Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000019382 nerve compression syndrome Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000037916 non-allergic rhinitis Diseases 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940087480 norpramin Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 208000007892 occupational asthma Diseases 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- OGQDIIKRQRZXJH-UHFFFAOYSA-N protriptyline hydrochloride Chemical compound [Cl-].C1=CC2=CC=CC=C2C(CCC[NH2+]C)C2=CC=CC=C21 OGQDIIKRQRZXJH-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000050 smooth muscle relaxant Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000003890 substance P antagonist Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940041597 tofranil Drugs 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 208000037911 visceral disease Diseases 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 229940045977 vivactil Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
Description
R1は、C1−C6アルキル、(C1−C6アルキル)C1−C6アルキル、ジ−(C1−C6アルキル)C1−C6アルキル、C3−C6シクロアルキル、(C1−C6アルキル)アミノまたはジ−(C1−C6アルキル)アミノであり;
R2は、それぞれ独立して、ハロゲン、C1−C6アルキル、ハロゲン置換C1−C6アルキル、ヒドロキシC1−6アルキル、シアノまたは基−C(=O)−R2a(ここで、R2aは、C1−C6アルキルである。)であり;
R3は、水素、ハロゲン、C1−C6アルキル、C2−C6アルケニル、C2−C6アルキニル、ヒドロキシ、ヒドロキシ置換C1−C6アルキル、C1−C6アルコキシ、C3−C6シクロアルキル、シアノ、−C(=O)H、フェニル、(C3−C6シクロアルキル)C1−C6アルコキシ、(C1−C6アルコキシカルボニルアミノ)C1−C6アルコキシまたは(C1−C6アルキルカルボニルアミノ)C1−C6アルコキシであり;
R4は、ヒドロキシ、エステル化ヒドロキシ、エーテル化ヒドロキシ、アミノ、(C1−C6アルキル)アミノ、基
R5は、水素またはヒドロキシであり;そして
mは、1または2である。]
で示されるキナゾリノン化合物の使用に関する。
〔式中、R1は、C1−C6アルキル、(C1−C6アルキル)C1−C6アルキル、ジ−(C1−C6アルキル)C1−C6アルキルまたはC3−C6シクロアルキルであり;
R2は、それぞれ独立して、ハロ、C1−C6アルキル、トリ−ハロ置換C1−C6アルキル、ヒドロキシC1−C6アルキルまたは基
R3は、水素、ハロ、C1−C6アルキル、ヒドロキシ、C1−C6アルコキシまたは(C3−C6シクロアルキル)C1−C6アルコキシであり;
R4は、ヒドロキシ、エステル化ヒドロキシ、エーテル化ヒドロキシ、アミノ、(C1−C6アルキル)アミノ、基
または基
R5は、水素またはヒドロキシであり;そして
mは、1または2である。〕
で示されるキナゾリノン化合物の使用に関する。
R1は、C1−C6アルキル、(C1−C6アルキル)C1−C6アルキル、ジ−(C1−C6アルキル)C1−C6アルキル、C3−C6シクロアルキル、(C1−C6アルキル)アミノまたはジ−(C1−C6アルキル)アミノであり;
R2は、それぞれ独立して、ハロゲン、C1−C6アルキル、ハロゲン置換C1−C6アルキル、ヒドロキシC1−C6アルキル、シアノまたは基−C(=O)−R2a(ここで、R2aは、C1−C6アルキルである。)であり;
R3は、水素、ハロゲン、C1−C6アルキル、C2−C6アルケニル、C2−C6アルキニル、ヒドロキシ、ヒドロキシ置換C1−C6アルキル、C1−C6アルコキシ、C3−C6シクロアルキル、シアノ、−C(=O)H、フェニル、(C3−C6シクロアルキル)C1−C6アルコキシ、(C1−C6アルコキシカルボニルアミノ)C1−C6アルコキシまたは(C1−C6アルキルカルボニルアミノ)C1−C6アルコキシであり;
R4は、ヒドロキシ、エステル化ヒドロキシ、エーテル化ヒドロキシ、アミノ、(C1−C6アルキル)アミノ、基
R5は、水素またはヒドロキシであり;そして
mは、1または2である。]
で示される新規なキナゾリノン化合物に関する。
〔式中、R1は、C1−C6アルキル、(C1−C6アルキル)C1−C6アルキル、ジ−(C1−C6アルキル)C1−C6アルキルまたはC3−C6シクロアルキルであり;
R2は、それぞれ独立して、ハロ、C1−C6アルキル、トリ−ハロ置換C1−C6アルキル、ヒドロキシC1−C6アルキルまたは基
R3は、水素、ハロ、C1−C6アルキル、ヒドロキシ、C1−C6アルコキシまたは(C3−C6シクロアルキル)C1−C6アルコキシであり;
R4は、ヒドロキシ、エステル化ヒドロキシ、エーテル化ヒドロキシ、アミノ、(C1−C6アルキル)アミノ、基
または基
mは、1または2である。〕
で示される新規なキナゾリノン化合物に関する。
“C1−C6アルキル”は、直鎖または分枝鎖C1−C6−アルキル、例えば、メチル、エチル、n−プロピル、イソプロピル、n−ブチル、イソブチル、sec−ブチルまたはtert−ブチルを示す。
“C1−C6アルコキシ”は、直鎖または分枝鎖C1−C6−アルキル−オキシ、例えばメトキシ、エトキシ、n−プロポキシまたはイソプロポキシを示す。
“エステル化ヒドロキシ”は、アシルオキシ、好ましくはC1−C6アルカノイルオキシを示し、より好ましくはC1−C4アルカノイルオキシを示す。
“エーテル化ヒドロキシ”は、C1−C6アルコキシ、好ましくはC1−C4アルコキシを示す。
(a)R1は、C1−C4アルキル、(C1−C4アルキル)C1−C4アルキル、ジ−(C1−C4アルキル)C1−C4アルキルまたはシクロプロピルであり;
(b)R2は、それぞれ独立して、クロロ、フルオロ、C1−C4アルキル、トリフルオロ置換C1−C4アルキルであり、より好ましくはトリフルオロメチル、C1−C4アルキルカルボニルであり、より好ましくはメチルカルボニルまたはヒドロキシC1−C4アルキルであり、より好ましくはヒドロキシメチルであり;
(c)R3は、水素、クロロ、ブロモ、C1−C4アルキル、ヒドロキシ、C1−C4アルコキシまたは(C3−C6シクロアルキル)C1−C4アルコキシであり;そして
(d)R4は、ヒドロキシ、アミノ、(C1−C4アルキル)アミノまたは基
A.式(Ia)〔ここで、R1およびR2は上記に定義の通りであり、R3は、式Iの化合物について記載の通りであり、R4はアミノであり、そしてmは1である。〕の化合物を製造するための方法。
スキームBは、スキームAに記載の通りに製造された式3の7−アミノ置換キナゾリン−4−オン化合物を濃硫酸および硝酸ナトリウムを用いてサンドマイヤー反応を行い、式4の7−ヒドロキシ置換キナゾリン−4−オン化合物を得ることを含む。
上記の方法による反応混合物の後処理およびそのようにして得られた化合物の精製を、公知の方法に従い行うことができる。
酸付加塩を、公知の方法で遊離塩基から製造することができ、その逆も可能である。
R1が、C1−C4アルキル、(C1−C4アルキル)C1−C4アルキルまたはC3−C6シクロアルキルであり;
R2が、クロロ、フルオロ、C1−C4アルキル、トリフルオロ置換C1−C4アルキル、C1−C4アルキルカルボニルまたはヒドロキシC1−C4アルキルであり;
R3が、水素、クロロ、ブロモ、C1−C4アルキル、ヒドロキシ、C1−C4アルコキシまたは(C3−C6シクロアルキル)C1−C4アルコキシであり;
R4が、ヒドロキシ、アミノまたは(C1−C4アルキル)アミノであり;
R5が、水素またはヒドロキシであり;そして
mが、1または2であるものである。
R1が、C1−C4アルキル、(C1−C4アルキル)C1−C4アルキルまたはC3−C6シクロアルキルであり;
R2が、クロロ、フルオロ、C1−C4アルキル、トリフルオロメチル、メチルカルボニルまたはヒドロキシメチルであり;
R3が、水素、クロロ、ブロモ、C1−C4アルキル、ヒドロキシまたはC1−C4アルコキシであり;
R4が、ヒドロキシ、アミノまたは(C1−C4アルキル)アミノであり;
R5が、水素またはヒドロキシであり;そして
mが1であるものである。
R1が、C1−C4アルキル、(C1−C4アルキル)C1−C4アルキルまたはC3−C6シクロアルキルであり;
R2が、クロロ、フルオロ、C1−C4アルキル、トリフルオロ置換C1−C4アルキル、C1−C4アルキルカルボニルまたはヒドロキシC1−C4アルキルであり;
R3が、水素、クロロ、ブロモ、C1−C4アルキル、ヒドロキシ、C1−C4アルコキシまたは(C3−C6シクロアルキル)C1−C4アルコキシであり;
R4が、ヒドロキシ、アミノまたは(C1−C4アルキル)アミノであり;そして
mが、1または2であるものである。
R1が、C1−C4アルキル、(C1−C4アルキル)C1−C4アルキルまたはC3−C6シクロアルキルであり;
R2が、クロロ、フルオロ、C1−C4アルキル、トリフルオロメチル、メチルカルボニルまたはヒドロキシメチルであり;
R3が、水素、クロロ、ブロモ、C1−C4アルキル、ヒドロキシ、C1−C4アルコキシまたは(C3−C6シクロアルキル)C1−C4アルコキシであり;
R4が、ヒドロキシ、アミノまたは(C1−C4アルキル)アミノであり;そして
mが1であるものである。
カプサイシン分析の日、培地を吸引し、そして細胞を、100μLの10mM N−2−(ヒドロキシエチルピペラジン−N’−[2−エタン−スルホン酸](HEPES)緩衝ハンクス平衡塩溶液(HBSS)、pH7.4を用いて洗浄した。その後、細胞を、0.01% pluronic F−127を含むHEPES緩衝HBSS中に調製された、2.3μMのレシオメトリックカルシウム結合色素フラ−2/AM(Molecular Probesから購入)を用いて40分間インキュベートした。pH分析について、HEPESを除き、そしてHBSSのpHを7.4に調節した。100μLの分析緩衝液で2回洗浄後、細胞を、0.001から30μMの間の濃度で、デュプリケートで、100μLの試験化合物(HBSS中に調製、pH7.4)と共に10分間インキュベートした。その後、前記プレートを、Molecular Devices社のFlexstation中に置いた。前記TRPV1受容体を、カプサイシンまたは低pHのいずれかの適用により刺激した。可能性のある拮抗作用について化合物の効果を試験するため、カプサイシンをEC80濃度で用い、それは、ラットTRPV1受容体について0.05μM、そしてヒトおよびモルモットについて0.1μMであった。pH試験のために、低pH緩衝溶液[HBSS中60mM 2−[N−モルホリノ]エタンスルホン酸(MES)]を、分析ウェルに加え、最終pH5.5とした。
(1)バニロイド受容体ブロッカーとしての使用を目的とした、例えば上記の特定の適応症のいずれかにおける使用を目的とした、遊離型または塩形態、および可能なときは薬学的に許容される酸付加塩形態の式(I)または(Ia)の化合物;
7−アミノ−3−(4−クロロフェニル)−2−イソプロピル−3H−キナゾリン−4−オンの製造
a)3−(4−クロロフェニル)−2−イソプロピル−7−ニトロ−3H−キナゾリン−4−オンの製造
トルエン(150mL)中、4−ニトロアントラニル酸イソブチルアミド(4g、15.8mmol)、4−クロロアニリン(2.2g、17.2mmol)および三塩化リン(5.6mL)の懸濁液を、2時間加熱還流する(150℃の浴温度)。反応混合物を室温まで冷却し、その後、乾燥するまで蒸発させる。残渣を、水とEtOAcの間に分配させ、水相をEtOAcで抽出する(2×)。合わせた有機相を水で洗浄し、乾燥させ(Na2SO4)、そして真空で蒸発させる。イソプロピルエーテルで粉末化し、所望の化合物を褐色固体として得る。
上記実施例1aで製造した化合物の混合物(2.4g、6.98mmol)、鉄粉(1.16g、20.8mmol)および氷酢酸(70mL)を、50℃で2.5時間撹拌する。反応混合物を室温まで冷却し、その後、乾燥するまで真空で蒸発させる。残渣を、水とEtOAcの間に分配させ、水相をEtOAcで抽出する(2×)。合わせた有機相を水で洗浄し、乾燥させ(Na2SO4)、そして真空で蒸発させ、褐色固体を得る。自動フラッシュクロマトグラフィー(勾配溶出:EtOAc/DCM0−50%)により精製し、淡黄色固体として表題化合物を得る。
(M+H)+=314.2;HPLC保持時間=3.9分。
3−(4−クロロフェニル)−7−ヒドロキシ−2−イソプロピル−3H−キナゾリン−4−オンの製造
氷浴温度に冷却した、濃硫酸/水972μL/1.4mL中、実施例1の化合物(778mg、2.479mmol)の懸濁液に、水中硝酸ナトリウム(188mg)の溶液(680μL)を添加する。混合物を、0−5℃(内部温度)で45分間撹拌し、次いで硫酸/水 3/2(5mL)を添加し、150℃まで予め加熱する。15分間撹拌後、その混合物を室温まで冷却し、ろ過し、そしてEtOAcで抽出する(3×)。合わせたEtOAc抽出物を水で洗浄し、乾燥させ(Na2SO4)、蒸発させ、黄色−オレンジ色固体とする。自動フラッシュクロマトグラフィー(勾配溶出:EtOAc/ヘキサン0−25%)により精製し、表題化合物を黄色固体として得る。
1H NMR (400 MHz, MeOH-d4): δ 7.91 (1H, d, J=8.7 Hz), 7.49 (2H, d, J=9.5 Hz), 7.25 (2H, J=9.5 Hz), 6.93 (1H, d, J=2.3 Hz), 6.86 (1H, dd, J=2.3, 8.7 Hz), 2.56 (1H, quint, J=6.7 Hz), 1.11 (6H, d, J=6.7 Hz);(M+H)+=315.8;HPLC保持時間=4.2分。
実施例3から28の化合物を、前記実施例に記載の方法と同様に製造することができる。
化合物29.1から29.54を、前記実施例に記載の方法と同様に製造することができる。
軟ゼラチンカプセルの製造
活性成分として0.05gの前記実施例に記載の式(Ia)の化合物のうち1つをそれぞれ含む5000個の軟ゼラチンカプセルを、下記の通りに製造する:
活性成分 250g
Lauroglycol(登録商標) 2l
Claims (5)
- 遊離型または薬学的に許容される塩形態の、式
R1は、C1−C6アルキル、(C1−C6アルキル)C1−C6アルキル、ジ−(C1−C6アルキル)C1−C6アルキルまたはC3−C6シクロアルキルであり;
R2は、それぞれ独立して、シアノまたは基−C(=O)−R2a(ここで、R2aは、C1−C6アルキルである。)であり;
R3は、水素、ハロゲン、C1−C6アルキル、C2−C6アルケニル、C2−C6アルキニル、ヒドロキシ、ヒドロキシ置換C1−C6アルキル、C1−C6アルコキシ、C3−C6シクロアルキル、シアノ、−C(=O)H、フェニル、(C3−C6シクロアルキル)C1−C6アルコキシ、(C1−C6アルコキシカルボニルアミノ)C1−C6アルコキシまたは(C1−C6アルキルカルボニルアミノ)C1−C6アルコキシであり;
R4は、ヒドロキシ、エーテル化ヒドロキシ、基
mは、1または2である。]
で示されるキナゾリノン化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0412769.2 | 2004-06-08 | ||
GBGB0412769.2A GB0412769D0 (en) | 2004-06-08 | 2004-06-08 | Organic compounds |
PCT/EP2005/006253 WO2005120510A1 (en) | 2004-06-08 | 2005-06-08 | Quinazolinone derivatives useful as vanilloid antagonists |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011010997A Division JP5400812B2 (ja) | 2004-06-08 | 2011-01-21 | バニロイドアンタゴニストとして有用なキナゾリノン誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008501763A JP2008501763A (ja) | 2008-01-24 |
JP4703650B2 true JP4703650B2 (ja) | 2011-06-15 |
Family
ID=32696854
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007526311A Active JP4703650B2 (ja) | 2004-06-08 | 2005-06-08 | バニロイドアンタゴニストとして有用なキナゾリノン誘導体 |
JP2011010997A Active JP5400812B2 (ja) | 2004-06-08 | 2011-01-21 | バニロイドアンタゴニストとして有用なキナゾリノン誘導体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011010997A Active JP5400812B2 (ja) | 2004-06-08 | 2011-01-21 | バニロイドアンタゴニストとして有用なキナゾリノン誘導体 |
Country Status (30)
Country | Link |
---|---|
US (4) | US7960399B2 (ja) |
EP (1) | EP1755606B2 (ja) |
JP (2) | JP4703650B2 (ja) |
KR (2) | KR20100101017A (ja) |
CN (1) | CN1956721B (ja) |
AT (1) | ATE376833T1 (ja) |
AU (2) | AU2005251476C1 (ja) |
BR (1) | BRPI0511933B8 (ja) |
CA (1) | CA2567821C (ja) |
CY (1) | CY1107846T1 (ja) |
DE (1) | DE602005003128T3 (ja) |
DK (1) | DK1755606T4 (ja) |
EC (2) | ECSP067067A (ja) |
ES (1) | ES2293584T5 (ja) |
GB (1) | GB0412769D0 (ja) |
HK (1) | HK1105577A1 (ja) |
HR (1) | HRP20070577T4 (ja) |
IL (1) | IL179532A (ja) |
MA (1) | MA28685B1 (ja) |
MX (1) | MXPA06014249A (ja) |
NO (1) | NO338181B1 (ja) |
NZ (1) | NZ551630A (ja) |
PL (1) | PL1755606T5 (ja) |
PT (1) | PT1755606E (ja) |
RU (2) | RU2449995C2 (ja) |
SG (1) | SG153811A1 (ja) |
SI (1) | SI1755606T2 (ja) |
TN (1) | TNSN06405A1 (ja) |
WO (1) | WO2005120510A1 (ja) |
ZA (1) | ZA200609634B (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
GB0525068D0 (en) * | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
CA2660957C (en) | 2006-08-23 | 2016-10-11 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
EP2094704A4 (en) * | 2006-11-06 | 2010-12-08 | Neurogen Corp | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES |
WO2009010529A1 (en) * | 2007-07-18 | 2009-01-22 | Novartis Ag | Synergistic combinations of vr-1 antagonists and cox-2 inhibitors |
US8915362B2 (en) | 2008-10-08 | 2014-12-23 | Ultimed, Inc. | Sharps container |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
EP2531510B1 (en) | 2010-02-01 | 2014-07-23 | Novartis AG | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
EA201491990A1 (ru) | 2012-05-03 | 2015-02-27 | Новартис Аг | L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов |
JP2016510749A (ja) | 2013-03-05 | 2016-04-11 | ユニヴァーシティー オブ ノートル ダム デュ ラック | キナゾリノン抗生物質 |
US10016425B2 (en) | 2016-11-03 | 2018-07-10 | King Saud University | Anti-ulcerative colitis compound |
SG11202103839UA (en) | 2018-10-31 | 2021-05-28 | Gilead Sciences Inc | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
US20220162170A1 (en) | 2019-02-15 | 2022-05-26 | Novartis Ag | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof |
CA3130038A1 (en) * | 2019-02-15 | 2020-08-20 | Novartis Ag | Methods for treating ocular surface pain |
JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤 |
TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
RU2755206C1 (ru) | 2020-05-20 | 2021-09-14 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство пролонгированного анальгетического действия и лекарственный препарат на его основе |
EP4192466A1 (en) | 2020-08-06 | 2023-06-14 | Novartis AG | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof |
US20230416207A1 (en) * | 2020-11-17 | 2023-12-28 | Crystal Pharmatech Co., Ltd. | Crystalline forms of quinazolinone compound and process for preparing the same |
AR125196A1 (es) | 2021-03-26 | 2023-06-21 | Novartis Ag | Derivados de ciclobutilo 1,3-sustituidos y sus usos |
WO2024062389A1 (en) | 2022-09-21 | 2024-03-28 | Bausch + Lomb Ireland Limited | Crystalline polymorph forms of a trpv1 antagonist and formulations thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1003802A (en) * | 1963-06-04 | 1965-09-08 | Searle & Co | Pyrimidinone derivatives |
FR1412615A (fr) * | 1963-10-09 | 1965-10-01 | Boehringer Sohn Ingelheim | Procédé pour fabriquer des nouvelles 2-méthyl-3-phényl-3h-4-quinazolones |
DE1232152B (de) * | 1962-06-27 | 1967-01-12 | Heyden Chem Fab | Verfahren zur Herstellung von 3-Phenylchinazolinon-(4)-derivaten |
JPS62193605A (ja) * | 1986-02-20 | 1987-08-25 | Toray Ind Inc | 半透性複合膜の製造方法 |
WO1992013535A1 (en) * | 1991-02-06 | 1992-08-20 | Research Corporation Technologies, Inc. | Anticonvulsant substituted quinazolones |
JPH10259176A (ja) * | 1997-03-17 | 1998-09-29 | Japan Tobacco Inc | 血管新生阻害作用を有する新規アミド誘導体及びその用途 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US82365A (en) * | 1868-09-22 | thompson | ||
US49728A (en) * | 1865-09-05 | Improvement | ||
US220227A (en) * | 1879-10-07 | Improvement in stri klng-movements for clocks | ||
US95650A (en) * | 1869-10-12 | Improvement in machines for bending sheet-metal for cornices | ||
DE239090C (ja) | 1906-11-01 | |||
US2749344A (en) | 1953-01-02 | 1956-06-05 | Burroughs Wellcome Co | Pyrimidine compounds |
DE1224316B (de) | 1961-03-18 | 1966-09-08 | Beiersdorf & Co Ag P | Verfahren zur Herstellung von 2-Methyl-3-(o-aethylphenyl)-4-oxo-3, 4-dihydrochinazolin und dessen Salzen |
US3515787A (en) * | 1962-06-27 | 1970-06-02 | Squibb & Sons Inc | Compositions and methods for producing a muscle relaxing effect in an animal with 2,3 - substituted - 6 - amino-4-quinazolones |
US3317388A (en) | 1964-11-20 | 1967-05-02 | Wallace & Tiernan Inc | Methods for treating pain |
US3864362A (en) | 1970-05-27 | 1975-02-04 | Chinoin Gyogyszer Es Vegyeszet | Iso flavones |
BE793594A (fr) | 1972-01-03 | 1973-07-02 | Pfizer | Nouvelles 6,7-dimethoxyquinazolines utiles comme analgesiques et tranquillisants |
GB1495305A (en) | 1975-09-12 | 1977-12-14 | Pfizer Ltd | 3-phenyl-4-oxo-4h-benzopyran derivatives |
US4501755A (en) | 1981-05-01 | 1985-02-26 | Pennwalt Corporation | Isoflavones useful as anti-inflammatory agents |
JPS59128376A (ja) * | 1983-01-13 | 1984-07-24 | Tanabe Seiyaku Co Ltd | キナゾリノン誘導体 |
SU1262927A1 (ru) | 1985-01-09 | 1997-11-20 | Институт физико-органической химии и углехимии АН УССР | Способ получения 6-бром-5-метилимидазо(4,5-в)пиридина |
JPS62201882A (ja) | 1985-11-18 | 1987-09-05 | Yamanouchi Pharmaceut Co Ltd | イソフラボン誘導体 |
ZA873745B (en) | 1986-06-04 | 1988-10-26 | Daiichi Seiyaku Co | Benzopyran derivatives |
US5290780A (en) * | 1991-01-30 | 1994-03-01 | American Cyanamid Co. | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
US5294617A (en) | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
US5284853A (en) | 1993-04-23 | 1994-02-08 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
EP0635263A3 (en) | 1993-06-28 | 1995-09-27 | American Cyanamid Co | Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue. |
HUT68558A (en) | 1993-07-20 | 1995-06-28 | Chinoin Gyogyszer Es Vegyeszet | Method for preparing isoflavon derivatives |
AU1599395A (en) | 1994-01-03 | 1995-08-01 | Cocensys, Inc. | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor |
JPH07258224A (ja) | 1994-03-24 | 1995-10-09 | Dai Ichi Seiyaku Co Ltd | 二環性化合物 |
US5756502A (en) * | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
ATE208763T1 (de) * | 1995-03-14 | 2001-11-15 | Novartis Erfind Verwalt Gmbh | Trisubstituierte phenyl derivate |
US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
WO1997028118A1 (en) | 1996-02-05 | 1997-08-07 | Hoechst Celanese Corporation | Process for preparing anthranilic acids |
WO1997044041A1 (en) | 1996-05-20 | 1997-11-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
FR2750862B1 (fr) | 1996-07-12 | 1998-10-16 | Dupin Jean Pierre | Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques |
AU6908398A (en) | 1996-10-28 | 1998-05-22 | Versicor Inc | Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones |
IT1289154B1 (it) | 1997-01-03 | 1998-09-29 | Chiesi Farma Spa | Derivati di isoflavone loro preparazione e loro impiego terapeutico |
US5948775A (en) | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
WO1999009140A1 (en) | 1997-08-20 | 1999-02-25 | The Regents Of The University Of California | Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof |
JP2002503451A (ja) | 1998-01-22 | 2002-02-05 | ザ・レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | カプサイシン受容体をコードする核酸配列 |
CA2322162A1 (en) | 1998-02-25 | 1999-09-02 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
ATE312812T1 (de) | 1999-02-22 | 2005-12-15 | Pacific Corp | Vanilloid-analoge die resiniferatoxin- pharmacophore enthalten als wirksame vanilloid rezeptor agonisten und analgetika, zusammensetzungen und ihre verwendung |
GB9920912D0 (en) | 1999-09-03 | 1999-11-10 | Indena Spa | Novel derivatives of flavones,xanthones and coumarins |
WO2001070228A1 (en) | 2000-03-17 | 2001-09-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
CA2415606A1 (en) | 2000-07-20 | 2002-01-31 | Neurogen Corporation | Capsaicin receptor ligands |
JP5001505B2 (ja) * | 2000-08-21 | 2012-08-15 | 株式會社アモーレパシフィック | 新規チオウレア誘導体およびこれを含有する薬学的組成物 |
FR2815033B1 (fr) | 2000-10-06 | 2003-09-05 | Negma Lab | Derives de 7-carboxy-flavones, porcede pour leur preparation et leur application en therapeutique |
EA007538B1 (ru) | 2000-12-11 | 2006-10-27 | Туларик Инк. | Антагонисты cxcr3 |
WO2002076946A2 (en) | 2001-03-26 | 2002-10-03 | Novartis Ag | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain. |
US20040259875A1 (en) * | 2001-07-31 | 2004-12-23 | Takeshi Yura | Amine derivatives |
GB0128499D0 (en) | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
IL147416A (en) * | 2001-12-31 | 2008-11-26 | Israel State | Combined modalities for improved cancer treatment |
US7074805B2 (en) * | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
US7381730B2 (en) | 2002-03-15 | 2008-06-03 | Bristol-Myers Squibb Company | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators |
AU2003238157A1 (en) † | 2002-06-18 | 2003-12-31 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
KR100647932B1 (ko) | 2002-07-05 | 2006-11-23 | 에프. 호프만-라 로슈 아게 | 퀴나졸린 유도체 |
EP1398032A1 (en) | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
US20060052345A1 (en) | 2002-11-04 | 2006-03-09 | Nps Pharmaceuticals, Inc. | Quinazolinone compounds as calcilytics |
EA009919B1 (ru) | 2003-02-11 | 2008-04-28 | Вернэлис (Кембридж) Лимитед | Соединения изоксазола |
EP1600440A1 (en) | 2003-03-06 | 2005-11-30 | Ono Pharmaceutical Co., Ltd. | Indole derivative compounds and drugs containing the compounds as the active ingredient |
JP2006193426A (ja) | 2003-09-05 | 2006-07-27 | Sankyo Co Ltd | 置換された縮環ピリミジン−4(3h)−オン化合物 |
WO2005040112A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
WO2005049613A1 (en) * | 2003-11-14 | 2005-06-02 | Merck Sharp & Dohme Limited | Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
NZ549046A (en) | 2004-02-13 | 2010-06-25 | Banyu Pharma Co Ltd | Fused-ring 4-oxopyrimidine derivative |
GB0412768D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
CA2607929A1 (en) | 2005-05-11 | 2006-11-16 | Merck Sharp & Dohme Limited | 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1) |
GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
WO2009010529A1 (en) | 2007-07-18 | 2009-01-22 | Novartis Ag | Synergistic combinations of vr-1 antagonists and cox-2 inhibitors |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
-
2004
- 2004-06-08 GB GBGB0412769.2A patent/GB0412769D0/en not_active Ceased
-
2005
- 2005-06-08 PT PT05750584T patent/PT1755606E/pt unknown
- 2005-06-08 BR BRPI0511933A patent/BRPI0511933B8/pt active IP Right Grant
- 2005-06-08 AU AU2005251476A patent/AU2005251476C1/en active Active
- 2005-06-08 AT AT05750584T patent/ATE376833T1/de active
- 2005-06-08 WO PCT/EP2005/006253 patent/WO2005120510A1/en active IP Right Grant
- 2005-06-08 DE DE602005003128T patent/DE602005003128T3/de active Active
- 2005-06-08 NZ NZ551630A patent/NZ551630A/en unknown
- 2005-06-08 KR KR1020107019024A patent/KR20100101017A/ko not_active Application Discontinuation
- 2005-06-08 CN CN200580016187.3A patent/CN1956721B/zh active Active
- 2005-06-08 RU RU2010112450/04A patent/RU2449995C2/ru active
- 2005-06-08 CA CA2567821A patent/CA2567821C/en active Active
- 2005-06-08 DK DK05750584.4T patent/DK1755606T4/da active
- 2005-06-08 MX MXPA06014249A patent/MXPA06014249A/es active IP Right Grant
- 2005-06-08 RU RU2006146632/04A patent/RU2396261C2/ru active
- 2005-06-08 SI SI200530141T patent/SI1755606T2/sl unknown
- 2005-06-08 SG SG200903909-0A patent/SG153811A1/en unknown
- 2005-06-08 JP JP2007526311A patent/JP4703650B2/ja active Active
- 2005-06-08 KR KR1020067025788A patent/KR101018607B1/ko active IP Right Grant
- 2005-06-08 PL PL05750584T patent/PL1755606T5/pl unknown
- 2005-06-08 ES ES05750584T patent/ES2293584T5/es active Active
- 2005-06-08 EP EP05750584A patent/EP1755606B2/en active Active
- 2005-06-08 US US11/569,802 patent/US7960399B2/en active Active
-
2006
- 2006-11-20 ZA ZA200609634A patent/ZA200609634B/xx unknown
- 2006-11-23 IL IL179532A patent/IL179532A/en active IP Right Grant
- 2006-12-07 EC EC2006007067A patent/ECSP067067A/es unknown
- 2006-12-07 TN TNP2006000405A patent/TNSN06405A1/en unknown
- 2006-12-28 MA MA29565A patent/MA28685B1/fr unknown
-
2007
- 2007-01-08 NO NO20070122A patent/NO338181B1/no unknown
- 2007-07-18 HK HK07107754A patent/HK1105577A1/xx active IP Right Maintenance
- 2007-12-20 HR HR20070577T patent/HRP20070577T4/hr unknown
-
2008
- 2008-01-03 CY CY20081100014T patent/CY1107846T1/el unknown
-
2009
- 2009-11-06 AU AU2009233684A patent/AU2009233684A1/en not_active Abandoned
-
2011
- 2011-01-21 JP JP2011010997A patent/JP5400812B2/ja active Active
- 2011-04-19 US US13/089,943 patent/US8211902B2/en active Active
-
2012
- 2012-02-14 EC ECSP12007067 patent/ECSP12007067A/es unknown
- 2012-03-29 US US13/434,248 patent/US8809528B2/en active Active
-
2014
- 2014-07-02 US US14/322,165 patent/US9102653B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1232152B (de) * | 1962-06-27 | 1967-01-12 | Heyden Chem Fab | Verfahren zur Herstellung von 3-Phenylchinazolinon-(4)-derivaten |
GB1003802A (en) * | 1963-06-04 | 1965-09-08 | Searle & Co | Pyrimidinone derivatives |
FR1412615A (fr) * | 1963-10-09 | 1965-10-01 | Boehringer Sohn Ingelheim | Procédé pour fabriquer des nouvelles 2-méthyl-3-phényl-3h-4-quinazolones |
JPS62193605A (ja) * | 1986-02-20 | 1987-08-25 | Toray Ind Inc | 半透性複合膜の製造方法 |
WO1992013535A1 (en) * | 1991-02-06 | 1992-08-20 | Research Corporation Technologies, Inc. | Anticonvulsant substituted quinazolones |
JPH10259176A (ja) * | 1997-03-17 | 1998-09-29 | Japan Tobacco Inc | 血管新生阻害作用を有する新規アミド誘導体及びその用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4703650B2 (ja) | バニロイドアンタゴニストとして有用なキナゾリノン誘導体 | |
JP2008501762A (ja) | バニロイドアンタゴニストとして有用なクロモン誘導体 | |
US20080293939A1 (en) | Quinazolinone derivatives useful as anti-hyperalgesic agents | |
SK284108B6 (sk) | 2,3-Disubstituované 4(3H)-chinazolinóny, ich použitie a farmaceutické kompozície s ich obsahom | |
BRPI0619540A2 (pt) | compostos de quinazolinona, seu uso, composição farmacêutica que os compreende e processo para a produção de um composto | |
JP2002538154A (ja) | セロトニン作動活性を有するn−置換イミド誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100817 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100921 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110121 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110208 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110301 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110308 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4703650 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |